Identification
NameFollitropin
Accession NumberDB00066  (BTD00099, BTD00064, BIOD00099, BIOD00064, DB09024)
TypeBiotech
GroupsApproved
Description

Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO). The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. Follitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable. However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels. Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH.

Protein structureDb00066
Related Articles
Protein chemical formulaC975H1513N267O304S26
Protein average weight22672.9 Da
Sequences
>Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>Beta chain
NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET
VRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE
Download FASTA Format
Synonyms
Follicle stimulating hormone
Follitrophin alfa
Follitrophin alpha
Follitrophin beta
Follitropin alfa
Follitropin alfa/beta
Follitropin alpha
Follitropin beta
Follitropin delta
Follitropin gamma
Follotropin recombinant
FSH
FSH alpha
FSH-a
FSH-b
FSH-beta
Recombinant human follicle stimulating hormone beta
Recombinant human follicle-stimulating hormone (r-HFSH)
rFSH-alpha
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BemfolaInjection, solution300 IU/0.50mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution300 IU/0.50mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution450 IU/0.75mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution225 IU/0.375mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution75 IU/0.125mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution225 IU/0.375mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution450 IU/0.75mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution300 IU/0.50mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution75 IU/0.125mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution150 IU/0.25mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution225 IU/0.375mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution150 IU/0.25mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution75 IU/0.125mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
BemfolaInjection, solution450 IU/0.75mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
Bemfola NeedlesInjection, solution150 IU/0.25mlSubcutaneousFinox Biotech Ag2014-03-27Not applicableEu
FertavidInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution900 IU/1.08mLSubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution300 IU/0.36mLSubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution600 IU/0.72mLSubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution150 IU/0.18mLSubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
FertavidInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited2009-03-19Not applicableEu
Follistim AQInjection, solution975 [iU]/1.17mLSubcutaneousOrganon2004-03-24Not applicableUs
Follistim AQInjection, solution650 [iU]/.78mLSubcutaneousOrganon2004-03-24Not applicableUs
Follistim AQInjection, solution150 [iU]/.5mLIntramuscular; SubcutaneousOrganon2010-06-28Not applicableUs
Follistim AQInjection, solution350 [iU]/.42mLSubcutaneousOrganon2004-03-24Not applicableUs
Follistim AQInjection, solution75 [iU]/.5mLIntramuscular; SubcutaneousOrganon2010-06-28Not applicableUs
Gonal-FInjection, powder, for solution75 IUSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FInjection, solution450 IU/0.75mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FKitSubcutaneousEmd Serono2004-03-25Not applicableUs
Gonal-FPowder, for solution37.5 unitIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada2001-01-112003-07-30Canada
Gonal-FInjection, powder, for solution75 IUSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FPowder, for solution5.5 mcgIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada2003-12-29Not applicableCanada
Gonal-FInjection, powder, for solution300 IU/0.5mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FInjection, powder, for solution1050 IU/1.75mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FPowder, for solution1200 unitIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada2001-11-232013-08-09Canada
Gonal-FInjection, solution900 IU/1.5mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FPowder, for solution75 unitIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada1997-07-252003-12-29Canada
Gonal-FInjection, powder, for solution75 IUSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FPowder, for solution33 mcgIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada2003-12-30Not applicableCanada
Gonal-FInjection, solution300 IU/0.5mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FKitSubcutaneousEmd Serono2004-03-25Not applicableUs
Gonal-FPowder, for solution150 unitIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada1997-07-252013-08-09Canada
Gonal-FInjection, powder, for solution75 IUSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FInjection, powder, for solution450 IU/0.75mlSubcutaneousMerck Serono Europe Limited1995-10-20Not applicableEu
Gonal-FPowder, for solution77 mcgIntramuscular; SubcutaneousEmd Serono, A Division Of Emd Inc., Canada2003-12-30Not applicableCanada
Gonal-F PenSolution300 unitSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2005-09-06Not applicableCanada
Gonal-F PenSolution900 unitSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2005-09-06Not applicableCanada
Gonal-F PenSolution450 unitSubcutaneousEmd Serono, A Division Of Emd Inc., Canada2005-09-06Not applicableCanada
Gonal-F RffKitSubcutaneousEmd Serono2004-03-25Not applicableUs
Gonal-F Rff PenInjection, solution450 [iU]/.75mLSubcutaneousEmd Serono2004-05-25Not applicableUs
Gonal-F Rff PenInjection, solution300 [iU]/.5mLSubcutaneousEmd Serono2004-05-25Not applicableUs
Gonal-F Rff PenInjection, solution900 [iU]/1.5mLSubcutaneousEmd Serono2004-05-25Not applicableUs
Gonal-F Rff Redi-jectInjection, solution300 [iU]/.5mLSubcutaneousEmd Serono2013-10-16Not applicableUs
Gonal-F Rff Redi-jectInjection, solution450 [iU]/.75mLSubcutaneousEmd Serono2013-10-16Not applicableUs
Gonal-F Rff Redi-jectInjection, solution900 [iU]/1.5mLSubcutaneousEmd Serono2013-10-16Not applicableUs
OvaleapInjection, solution450 IU/0.75mLSubcutaneousTeva Pharma B.V.2013-09-27Not applicableEu
OvaleapInjection, solution300 IU/0.5mLSubcutaneousTeva Pharma B.V.2013-09-27Not applicableEu
PuregonSolution50 unitIntramuscular; SubcutaneousMerck Ltd.2001-10-24Not applicableCanada
PuregonInjection, solution150 IU/0.18mLSubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution225 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution600 IU/0.72mLSubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonSolution100 unitIntramuscular; SubcutaneousMerck Ltd.2001-10-24Not applicableCanada
PuregonInjection, solution900 IU/1.08mLSubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution225 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution75 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution225 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution300 IU/0.36mLSubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonSolution833 unitSubcutaneousMerck Ltd.2001-10-18Not applicableCanada
PuregonInjection, solution150 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution100 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution50 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
PuregonInjection, solution200 IU/0.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1996-05-03Not applicableEu
Puregon (600 Iu)Solution737 unitSubcutaneousOrganon Canada Ltd Ltee2001-10-182005-07-07Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cinnal-FNot Available
FollistimOrganon
Brand mixtures
NameLabellerIngredients
PergoverisEmd Serono, A Division Of Emd Inc., Canada
Puregon 100 I.U.Organon Canada Ltd Ltee
Puregon 50 I.U.Organon Canada Ltd Ltee
Categories
UNII076WHW89TW
CAS number146479-72-3
Pharmacology
Indication

In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).

Structured Indications Not Available
Pharmacodynamics

Used for the treatment of female infertility, Follitropin beta or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Follitropin beta is the primary hormone responsible for follicular recruitment and development.

Mechanism of action

Follitropin is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.

TargetKindPharmacological actionActionsOrganismUniProt ID
Follicle-stimulating hormone receptorProteinyes
agonist
HumanP23945 details
Related Articles
Absorption

The absorption rate is the main driving force behind the pharmokinetics of Follitropin alpha as the rate of absorption was found to be slower than the elimination rate after administration subcutaneously and intramuscularly. The bioavailability is approximately 66-76%. The time to peak after subcutaneous injection in healthy volunteers was 8-16 hours in females and 11-20 hours in males.

Volume of distribution
  • 8 L [female subjects following intravenous administration of a 300 IU dose]
Protein bindingNot Available
MetabolismNot Available
Route of elimination

Via liver and kidneys.

Half life

Circulation half life of 3-4 hours, elimination half life of 35-40 hours

Clearance
  • 0.01 1*h-1kg-1 [European women with a single intramuscular dose of 300 IU]
  • 0.01 1*h-1kg-1 [Japanese women with a single intramuscular dose of 300 IU]
Toxicity

Headaches, ovarian cysts, nausea and upper respiratory tract infections occurred in more than 10% of women in clinical trials. In men, the most serious adverse events reported were testicular surgery for cryptorchidism which existed prestudy, hemoptysis, an infected pilonidal cyst, and lymphadenopathy associated with an Epstein-Barr viral infection. Other concerns include overstimulation of the ovaries, pulmonary and vascular complications and multiple births. Post-marketing reports revealed hypersensitivity reactions including anaphylactoid reactions and asthma. Follitropin is contraindicated in pregnant women. No studies have been done in nursing mothers.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions No interactions found.
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60. [PubMed:18020563 ]
External Links
ATC CodesG03GA05 — Follitropin alfaG03GA06 — Follitropin beta
AHFS CodesNot Available
PDB Entries
FDA labelDownload (468 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBioequivalence1
1, 2Enrolling by InvitationTreatmentFemale Infertility Due to Diminished Ovarian Reserve1
2CompletedTreatmentAssisted Reproductive Technology therapy / Infertilities1
2CompletedTreatmentControlled Ovarian Stimulation1
2CompletedTreatmentFertilization1
2CompletedTreatmentInfertilities4
2TerminatedTreatmentHypogonadism / Olfacto genital dysplasia1
2TerminatedTreatmentOvulation induction therapy2
2Unknown StatusTreatmentInfertilities1
2Unknown StatusTreatmentPolycystic Ovaries Syndrome1
2, 3CompletedTreatmentMale Infertility1
3Active Not RecruitingTreatmentInfertilities1
3CompletedNot AvailableInfertilities1
3CompletedTreatmentAnovulatory cycle2
3CompletedTreatmentAnovulatory cycle / Hypothalamic-pituitary Dysfunction / Oligo-ovulation / Polycystic Ovarian Syndrome1
3CompletedTreatmentAnovulatory cycle / Infertilities1
3CompletedTreatmentAssisted Reproductive Techniques / Reproductive Technology, Assisted1
3CompletedTreatmentHypogonadism1
3CompletedTreatmentIn-Vitro Fertilization / Infertilities / Ovulation induction therapy1
3CompletedTreatmentInfertilities10
3CompletedTreatmentInfertilities / Ovulation induction therapy2
3Not Yet RecruitingTreatmentInfertility, Female / Polycystic Ovaries Syndrome1
3RecruitingTreatmentInfertility, Female1
3TerminatedSupportive CareFertility / Follicle Stimulating Hormone Deficiency / Infertilities1
3WithdrawnTreatmentInfertilities1
4Active Not RecruitingTreatmentInfertilities3
4CompletedNot AvailableInfertilities1
4CompletedNot AvailableInfertilities / Premature Ovarian Failure (POF)1
4CompletedPreventionInfertilities1
4CompletedTreatmentAssisted Reproductive Technology therapy / Infertilities1
4CompletedTreatmentInfertile Women Undergoing Assisted Reproductive Technology (ART)1
4CompletedTreatmentInfertilities7
4CompletedTreatmentInfertilities / Polycystic Ovarian Syndrome1
4CompletedTreatmentOvulation induction therapy1
4CompletedTreatmentSubfertility1
4Not Yet RecruitingTreatmentInVitro Fertilization1
4Not Yet RecruitingTreatmentInfertilities3
4Not Yet RecruitingTreatmentInfertility, Female1
4Not Yet RecruitingTreatmentMale Infertility / Varicoceles1
4RecruitingSupportive CareAssisted Reproductive Technology therapy / Infertilities1
4RecruitingTreatmentEgg Donation1
4RecruitingTreatmentFemale Reproductive Problem / Infertilities1
4RecruitingTreatmentInfertilities1
4RecruitingTreatmentInfertility, Female1
4RecruitingTreatmentReproductive Techniques, Assisted1
4TerminatedTreatmentAssisted Reproductive Technology therapy2
4TerminatedTreatmentAssisted Reproductive Technology therapy / Intracytoplasmic Sperm Injection1
4TerminatedTreatmentAssisted Reproductive Technology therapy / Ovulation induction therapy1
4TerminatedTreatmentIdiopathic Hypogonadotropic Hypogonadism1
4TerminatedTreatmentInfertilities / Monofollicular Development1
4TerminatedTreatmentPatients for In Vitro Fertilization(IVF)Treatment1
4Unknown StatusTreatmentAneuploidy / Blastocyst Disintegration / Chemical Pregnancy / Complication of Implant / Embryo/Fetus Death1
4Unknown StatusTreatmentInfertilities2
Not AvailableCompletedNot AvailableAnovulatory cycle1
Not AvailableCompletedNot AvailableAssisted Reproductive Technology therapy1
Not AvailableCompletedNot AvailableFertilization in Vitro1
Not AvailableCompletedNot AvailableInfertilities2
Not AvailableCompletedNot AvailableInfertility, Subfertility1
Not AvailableCompletedNot AvailableMultifollicular Stimulation1
Not AvailableCompletedNot AvailableNeonates / Pregnancy2
Not AvailableCompletedNot AvailableOvulation induction therapy1
Not AvailableCompletedNot AvailablePolycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailablePregnancy1
Not AvailableCompletedScreeningPolycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentCompare Pregnancy Rates Between FSH Stimulation and FSH and / GnRH Antagonist1
Not AvailableCompletedTreatmentIdiopathic Hypogonadotropic Hypogonadism1
Not AvailableCompletedTreatmentInfertilities2
Not AvailableCompletedTreatmentSubfertility1
Not AvailableEnrolling by InvitationNot AvailableOocytes / Pregnancy Rate1
Not AvailableEnrolling by InvitationTreatmentInfertilities1
Not AvailableNot Yet RecruitingTreatmentInfertilities1
Not AvailableRecruitingNot AvailableInfertilities2
Not AvailableRecruitingTreatmentFertility / Infertilities1
Not AvailableTerminatedNot AvailableInfertilities1
Not AvailableTerminatedNot AvailableMultifollicular Stimulation1
Not AvailableUnknown StatusNot AvailableGalactose intolerance / Premature Ovarian Failure (POF)1
Not AvailableUnknown StatusNot AvailableSubfertility1
Not AvailableUnknown StatusTreatmentComplications Associated With Artificial Fertilization / Female Infertility Due to Nonimplantation of Ovum1
Not AvailableUnknown StatusTreatmentInfertility, Female1
Pharmacoeconomics
Manufacturers
  • Organon usa inc
  • Emd serono inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous150 IU/0.25ml
Injection, solutionSubcutaneous225 IU/0.375ml
Injection, solutionSubcutaneous300 IU/0.50ml
Injection, solutionSubcutaneous450 IU/0.75ml
Injection, solutionSubcutaneous75 IU/0.125ml
Injection, solutionIntramuscular; Subcutaneous150 [iU]/.5mL
Injection, solutionIntramuscular; Subcutaneous75 [iU]/.5mL
Injection, solutionSubcutaneous350 [iU]/.42mL
Injection, solutionSubcutaneous650 [iU]/.78mL
Injection, solutionSubcutaneous975 [iU]/1.17mL
Injection, powder, for solutionSubcutaneous1050 IU/1.75ml
Injection, powder, for solutionSubcutaneous300 IU/0.5ml
Injection, powder, for solutionSubcutaneous450 IU/0.75ml
Injection, powder, for solutionSubcutaneous75 IU
Injection, solutionSubcutaneous300 IU/0.5ml
Injection, solutionSubcutaneous900 IU/1.5ml
Powder, for solutionIntramuscular; Subcutaneous1200 unit
Powder, for solutionIntramuscular; Subcutaneous150 unit
Powder, for solutionIntramuscular; Subcutaneous33 mcg
Powder, for solutionIntramuscular; Subcutaneous37.5 unit
Powder, for solutionIntramuscular; Subcutaneous5.5 mcg
Powder, for solutionIntramuscular; Subcutaneous75 unit
Powder, for solutionIntramuscular; Subcutaneous77 mcg
SolutionSubcutaneous300 unit
SolutionSubcutaneous450 unit
SolutionSubcutaneous900 unit
KitSubcutaneous
Injection, solutionSubcutaneous300 [iU]/.5mL
Injection, solutionSubcutaneous450 [iU]/.75mL
Injection, solutionSubcutaneous900 [iU]/1.5mL
Kit; powder, for solutionSubcutaneous
Injection, solutionIntramuscular; Subcutaneous100 IU/0.5mL
Injection, solutionIntramuscular; Subcutaneous150 IU/0.5mL
Injection, solutionIntramuscular; Subcutaneous200 IU/0.5mL
Injection, solutionIntramuscular; Subcutaneous225 IU/0.5mL
Injection, solutionIntramuscular; Subcutaneous50 IU/0.5mL
Injection, solutionIntramuscular; Subcutaneous75 IU/0.5mL
Injection, solutionSubcutaneous150 IU/0.18mL
Injection, solutionSubcutaneous300 IU/0.36mL
Injection, solutionSubcutaneous600 IU/0.72mL
Injection, solutionSubcutaneous900 IU/1.08mL
SolutionIntramuscular; Subcutaneous100 unit
SolutionIntramuscular; Subcutaneous50 unit
SolutionSubcutaneous833 unit
SolutionSubcutaneous737 unit
Liquid; powder, for solutionIntramuscular; Subcutaneous
Prices
Unit descriptionCostUnit
Gonal-f rff 900 unit pen1409.62USD ml
Follistim AQ 900unt/1.08ml Solution 1 Cartridge = 1.17ml1366.71USD cartridge
Follistim AQ 600unt/0.72ml Solution 0.78ml Cartridge911.14USD cartridge
Gonal-f 450 unit Solution Vial733.0USD vial
Gonal-f rff 450 unit pen704.81USD pen
Gonal-f rff 300 unit pen469.87USD pen
Follistim AQ 300unt/0.36ml Solution 0.42ml Cartridge455.57USD cartridge
Follistim aq 300 unit cartridge438.05USD cartridge
Follistim aq 150 unit vial219.02USD vial
Gonal-f rff 75 unit vial117.47USD vial
Follistim aq 75 unit vial109.51USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2037884 No2003-10-212011-03-08Canada
US5270057 No1994-03-202011-03-20Us
US5929028 No1998-01-142018-01-14Us
US7446090 No1999-08-232019-08-23Us
US7563763 No1999-08-232019-08-23Us
US7741268 No2004-04-022024-04-02Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)55 °CForastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)
hydrophobicity-0.330Not Available
isoelectric point7.50Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled peptide receptor activity
Specific Function:
Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Induces cAMP production through the activation of PI3K-AKT and SRC-ERK1/2 signaling pathways.
Gene Name:
FSHR
Uniprot ID:
P23945
Molecular Weight:
78264.07 Da
References
  1. Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10. [PubMed:11299519 ]
  2. Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9. [PubMed:7755615 ]
  3. Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200. [PubMed:2108722 ]
  4. Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46. [PubMed:8319832 ]
  5. Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40. [PubMed:8070368 ]
  6. Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60. [PubMed:18020563 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Drug created on June 13, 2005 07:24 / Updated on July 22, 2017 12:04